|Bid||135.03 x 1200|
|Ask||135.90 x 900|
|Day's range||126.53 - 136.13|
|52-week range||119.01 - 497.49|
|Beta (5Y monthly)||1.70|
|PE ratio (TTM)||3.99|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) both delivered major returns for investors in the early days of the coronavirus vaccine race. Moderna's vaccine entered the market in December of 2020. Novavax's vaccine began winning authorizations a year later -- but isn't yet approved in the United States.
Successful money managers used the Nasdaq bear market as a catalyst to buy into these high-growth stocks.
AstraZeneca's (AZN) third/booster dose of its COVID-19 vaccine gets authorized in Europe for use in adults, both for homologous and heterologous use.